China Approves Rilzabrutinib for Persistent or Chronic ITP

Evidence Regulatory disclosure · Discovery September 11, 2026 · Importance 5/5 · Direction Positive Summary China’s National Medical Products Administration approved Genzyme Corporation’s rilzabrutinib tablets, branded Sailizhi in China, for adults with persistent or chronic primary immune thrombocytopenia who respond inadequately to or cannot tolerate…